Comparative Pharmacology
Head-to-head clinical analysis: NEOMYCIN POLYMYXIN B SULFATES BACITRACIN ZINC HYDROCORTISONE versus U GENCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEOMYCIN POLYMYXIN B SULFATES BACITRACIN ZINC HYDROCORTISONE versus U GENCIN.
NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE vs U-GENCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neomycin, polymyxin B, and bacitracin are antibiotics that inhibit bacterial protein synthesis, disrupt cell membrane integrity, and interfere with cell wall synthesis, respectively. Hydrocortisone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis.
Apply to affected area 3-4 times daily. Not for use in eyes.
1-2 mg/kg IV every 8 hours for 7-10 days, targeting peak serum concentration of 6-10 mcg/mL and trough <2 mcg/mL.
None Documented
None Documented
Neomycin: 2-3h (normal renal); polymyxin B: 4-6h (normal renal), prolonged to 2-3 days in renal impairment; bacitracin: ~1.5h after IM; hydrocortisone: 1.5-2h (plasma). Topical: systemic levels negligible.
Terminal elimination half-life is 2-3 hours in patients with normal renal function; may prolong to 20-40 hours in end-stage renal disease
Neomycin: >90% renal (unchanged) after parenteral; polymyxin B: ~60% renal (unchanged) over 72h; bacitracin: >90% renal (unchanged) after IM; hydrocortisone: hepatic metabolism, metabolites renally eliminated (<1% unchanged). Topical: negligible systemic absorption across intact skin (except bacitracin may be minimally absorbed).
Primarily renal (glomerular filtration) with 40-70% excreted unchanged in urine within 24 hours; minor biliary/fecal (<5%)
Category A/B
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic